ACP
VKTX icon

Acuta Capital Partners’s Viking Therapeutics VKTX Stock Holding History

Acuta Capital Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,000
Closed -$233K – 43
2023
Q1 		$233K Buy
+14,000
New +$145K 0.17% 31
2018
Q3 		– Sell
-750,000
Closed -$7.12M – 50
2018
Q2 		$7.12M Buy
+750,000
New +$4.99M 1.27% 18

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Acuta Capital Partners's VKTX Position: Q2 2023 in Review

Acuta Capital Partners sold out of Viking Therapeutics (VKTX) in Q2 2023, closing a stake of 14,000 shares — an estimated $233K sold.

Acuta Capital Partners first reported a position in VKTX in Q2 2018 and held it in 2 quarters. The position peaked at $7.12M in Q2 2018. 193 funds tracked by Wall St. Rank hold VKTX as of Q2 2023.

  • Acuta Capital Partners reported no remaining Viking Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 14,000 Viking Therapeutics shares in Q2 2023, an estimated $233K.
  • Acuta Capital Partners first reported a position in Viking Therapeutics in Q2 2018 and held it in 2 quarters.
  • Acuta Capital Partners's Viking Therapeutics position peaked at $7.12M in Q2 2018.
  • 193 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2023.

Based on Acuta Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.